Integrated Filing — IndAS



General information about company

Scrip Code 544709
NSE Symbol GAUDIUMIVF
MSEI Symbol NOTLISTED
ISIN INE0P8B01020
Name of company GAUDIUM IVF AND WOMEN HEALTH LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 28-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Health Care Business
Start date and time of board meeting 28-05-2026   16:00:00
End date and time of board meeting 28-05-2026   18:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 04-11-2024
Indicate Company website link for updated RPT policy of the Company https://www.gaudiumivfcentre.com/assets/fornt/images/pdf/corporate-policies/Policy%20Related%20Party%20Transaction.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclousre for default on loans and debt securities is not applicable to the Company since there have been no defaults on loans during the year under review



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 2,216.60 7,157.85
Other income 17.66 49.81
Total income 2,234.26 7,207.66
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 85.87 450.20
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 34.23 24.60
(d) Employee benefit expense 203.07 772.43
(e) Finance costs 123.62 336.19
(f) Depreciation, depletion and amortisation expense 60.85 243.66
(f) Other Expenses
1 Other expenses 547.98 1,609.43
2 Cost of rendering services 219.30 844.60
Total other expenses 767.28 2,454.03
Total expenses 1,274.92 4,281.11
3 Total profit before exceptional items and tax 959.34 2,926.55
4 Exceptional items 0.00 0.00
5 Total profit before tax 959.34 2,926.55
6 Tax expense
7 Current tax 189.07 704.25
8 Deferred tax (2.87) (6.47)
9 Total tax expenses 186.20 697.78
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 773.14 2,228.77
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 773.14 2,228.77
17 Other comprehensive income net of taxes 1.79 7.57
18 Total Comprehensive Income for the period 774.93 2,236.34
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 3,639.34 3,639.34
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve 11,287.14
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.24 3.59
Diluted earnings (loss) per share from continuing operations 1.24 3.59
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.24 3.59
Diluted earnings (loss) per share from continuing and discontinued operations 1.24 3.59
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes to Statement of Standalone Financial Results 1.The standalone financial results for the quarter and year ended March 31, 2026 ('the Results') of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2.These standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on May 28, 2026. The statutory auditors have carried out an audit of the standalone financial results for the year ended March 31, 2026 and have issued an unmodified opinion on the same. 3.The figures for the quarters ended March 31, 2026 and March 31, 2025, represent the differences between the audited annual financial results for the years ended March 31, 2026 and March 31, 2025, and the unaudited quarterly results upto December 31, 2025 and December 31, 2024, respectively. The unaudited standalone financial results for the nine months ended December 31, 2024 were approved by the Board of Directors of the Company. The statutory auditors have not carried out limited review procedures on the standalone financial results for the nine months ended December 31, 2024. 4.The operating segment of the Company is identified as Health Care Business, as the Chief Operating Decision Maker reviews business performance at an overall company level as one segment. Therefore, the disclosure as per Regulation 33(1)(e) read with Clause (L) of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company. 5.The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes, collectively referred to as the “New Labour Codes”. These Codes, inter alia, introduce a revised definition of “Wages” for the purpose of computation of various employee benefits. The Company has evaluated the potential impact of the revised definition of wages on its employee benefit obligations. Considering that the Company already structures employee compensation in accordance with the revised definition of wages under the New Labour Codes is not expected to have a material impact on the computation of employee benefits such as gratuity and compensated absences. Accordingly, no additional liability or past service cost has been recognised in the financial results for the quarter and year ended March 31, 2026. The Company will continue to monitor developments relating to the implementation of the New Labour Codes and will reassess the impact, if any, upon notification of the final rules. 6.During the year The Company has completed its Initial Public Offer (IPO) of 20886200 equity shares of face value of Rs 5 each at an issue price of Rs 79 per share including a share premium of Rs 74 per share. The issue comprised of a fresh issue of 11392500 equity shares aggregating to Rs 9000.08 Lakhs and offer for sale of 9493700 equity shares by selling shareholder aggregating to Rs 7500.02 Lakhs. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on February 27 2026. The utilisation of IPO proceeds (in Rs Lakhs) is as follows. For Funding capital expenditure towards establishment of New IVF Centers of our Company amount to be utilised as per prospectus is 5000.00 Lakhs and amount utilised upto March 31 2026 is 0.00 and amount remaining unutilised is 5000.00 Lakhs. For Repayment or pre payment in full or in part of certain outstanding loans availed by our Company amount to be utilised as per prospectus is 2000.00 Lakhs and amount utilised upto March 31 2026 is 0.00 and amount remaining unutilised is 2000.00 Lakhs. For General Corporate Purposes amount to be utilised as per prospectus is 1228.19 Lakhs and amount utilised upto March 31 2026 is 96.99 Lakhs and amount remaining unutilised is 1131.20 Lakhs. For Fresh issue related expenses amount to be utilised as per prospectus is 771.89 Lakhs and amount utilised upto March 31 2026 is 771.89 Lakhs and amount remaining unutilised is 0.00. The Total amount to be utilised as per prospectus is 9000.08 Lakhs Total amount utilised upto March 31 2026 is 868.88 Lakhs and Total amount remaining unutilised is 8131.20 Lakhs. 7. The figures for the corresponding previous periods have been regrouped / reclassified wherever necessary to conform to the current period presentation, and such regrouping does not have any impact on profit / loss of the Company. 8.The above financial results of the group are available on the holding Company’s website www.gaudiumivfcentre.com and also that of NSE (www.nseindia.com) and BSE (www.bseindia.com). 9. Item of expenditure which exceeds 10 percent of the total expenditure (in Rs In Lakhs) is as follows. For Sales and marketing expenses the amount for the Quarter ended March 31 2026 (Audited) is 233.70 Lakhs and amount for the Quarter ended December 31 2025 (Unaudited) is 126.72 Lakhs and amount for the Quarter ended March 31 2025 Unaudited is 165.39 Lakhs and amount for the Year ended March 31 2026 Audited is 672.97 Lakhs and amount for the Year ended March 31 2025 (Audited) is 560.82 Lakhs. For Rent the amount for the Quarter ended March 31 2026 (Audited) is 58.64 Lakhs and amount for the Quarter ended December 31 2025 (Unaudited) is 58.31 Lakhs and amount for the Quarter ended March 31 2025 (Unaudited) is 55.09 Lakhs and amount for the Year ended March 31 2026 (Audited) is 231.76 Lakhs and amount for the Year ended March 31 2025 Audited is 214.20 Lakhs. For Legal and professional fees the amount for the Quarter ended March 31 2026 (Audited) is 95.53 Lakhs and amount for the Quarter ended December 31 2025 (Unaudited) is 43.85 Lakhs and amount for the Quarter ended March 31 2025 (Unaudited) is 49.20 Lakhs and amount for the Year ended March 31 2026 (Audited) is 265.83 Lakhs and amount for the Year ended March 31 2025 (Audited) is 183.79 Lakhs.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 534.67
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 13.82
Other intangible assets 865.28
Intangible assets under development 1,196.83
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 625.00
Trade receivables, non-current
Loans, non-current 400.00
Other non-current financial assets
1 Right of Use Asset 121.62
2 Other Financial Assets 8,113.08
Total of other non-current financial assets 8,234.70
Total non-current financial assets 9,259.70
Deferred tax assets (net)
Other non-current assets
Total of other non-current assets
Total non-current assets 11,870.30
2 Current assets
Inventories 229.86
Current financial asset
Current investments 0.00
Trade receivables, current 4,260.42
Cash and cash equivalents 853.69
Bank balance other than cash and cash equivalents 0.00
Loans, current 0.00
Other current financial assets
Total of other current financial assets 520.86
Total current financial assets 5,634.97
Current tax assets (net)
Other current assets
1 Other current assets 123.46
Total of other current assets 123.46
Total current assets 5,988.29
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 17,858.59
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,639.34
Other equity 11,287.14
Total equity attributable to owners of parent 14,926.48
Non controlling interest
Total equity 14,926.48
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 128.26
Total of other non-current financial liabilities 128.26
Total non-current financial liabilities 128.26
Provisions, non-current 39.86
Deferred tax liabilities (net) 55.77
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 223.89
Current liabilities
Current financial liabilities
Borrowings, current 2,109.95
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 45.85
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 237.40
Total Trade payable 283.25
Other current financial liabilities
1 Lease Liabilities 21.28
2 other financial liabilities 77.20
Total of other current financial liabilities 98.48
Total current financial liabilities 2,491.68
Other current liabilities 81.94
1 Other current liabilities 81.94
Total of other current liabilities 81.94
Provisions, current 9.93
Current tax liabilities (Net) 124.67
Deferred government grants, Current
Total current liabilities 2,708.22
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2,932.11
Total equity and liabilites 17,858.59
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Notes to Statement of Standalone Financial Results 1.The standalone financial results for the quarter and year ended March 31, 2026 ('the Results') of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2.These standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on May 28, 2026. The statutory auditors have carried out an audit of the standalone financial results for the year ended March 31, 2026 and have issued an unmodified opinion on the same. 3.The figures for the quarters ended March 31, 2026 and March 31, 2025, represent the differences between the audited annual financial results for the years ended March 31, 2026 and March 31, 2025, and the unaudited quarterly results upto December 31, 2025 and December 31, 2024, respectively. The unaudited standalone financial results for the nine months ended December 31, 2024 were approved by the Board of Directors of the Company. The statutory auditors have not carried out limited review procedures on the standalone financial results for the nine months ended December 31, 2024. 4.The operating segment of the Company is identified as Health Care Business, as the Chief Operating Decision Maker reviews business performance at an overall company level as one segment. Therefore, the disclosure as per Regulation 33(1)(e) read with Clause (L) of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company. 5.The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes, collectively referred to as the “New Labour Codes”. These Codes, inter alia, introduce a revised definition of “Wages” for the purpose of computation of various employee benefits. The Company has evaluated the potential impact of the revised definition of wages on its employee benefit obligations. Considering that the Company already structures employee compensation in accordance with the revised definition of wages under the New Labour Codes is not expected to have a material impact on the computation of employee benefits such as gratuity and compensated absences. Accordingly, no additional liability or past service cost has been recognised in the financial results for the quarter and year ended March 31, 2026. The Company will continue to monitor developments relating to the implementation of the New Labour Codes and will reassess the impact, if any, upon notification of the final rules. 6.During the year The Company has completed its Initial Public Offer (IPO) of 20886200 equity shares of face value of Rs 5 each at an issue price of Rs 79 per share including a share premium of Rs 74 per share. The issue comprised of a fresh issue of 11392500 equity shares aggregating to Rs 9000.08 Lakhs and offer for sale of 9493700 equity shares by selling shareholder aggregating to Rs 7500.02 Lakhs. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on February 27 2026. The utilisation of IPO proceeds (in Rs Lakhs) is as follows. For Funding capital expenditure towards establishment of New IVF Centers of our Company amount to be utilised as per prospectus is 5000.00 Lakhs and amount utilised upto March 31 2026 is 0.00 and amount remaining unutilised is 5000.00 Lakhs. For Repayment or pre payment in full or in part of certain outstanding loans availed by our Company amount to be utilised as per prospectus is 2000.00 Lakhs and amount utilised upto March 31 2026 is 0.00 and amount remaining unutilised is 2000.00 Lakhs. For General Corporate Purposes amount to be utilised as per prospectus is 1228.19 Lakhs and amount utilised upto March 31 2026 is 96.99 Lakhs and amount remaining unutilised is 1131.20 Lakhs. For Fresh issue related expenses amount to be utilised as per prospectus is 771.89 Lakhs and amount utilised upto March 31 2026 is 771.89 Lakhs and amount remaining unutilised is 0.00. The Total amount to be utilised as per prospectus is 9000.08 Lakhs Total amount utilised upto March 31 2026 is 868.88 Lakhs and Total amount remaining unutilised is 8131.20 Lakhs. 7. The figures for the corresponding previous periods have been regrouped / reclassified wherever necessary to conform to the current period presentation, and such regrouping does not have any impact on profit / loss of the Company. 8.The above financial results of the group are available on the holding Company’s website www.gaudiumivfcentre.com and also that of NSE (www.nseindia.com) and BSE (www.bseindia.com). 9. Item of expenditure which exceeds 10 percent of the total expenditure (in Rs In Lakhs) is as follows. For Sales and marketing expenses the amount for the Quarter ended March 31 2026 (Audited) is 233.70 Lakhs and amount for the Quarter ended December 31 2025 (Unaudited) is 126.72 Lakhs and amount for the Quarter ended March 31 2025 Unaudited is 165.39 Lakhs and amount for the Year ended March 31 2026 Audited is 672.97 Lakhs and amount for the Year ended March 31 2025 (Audited) is 560.82 Lakhs. For Rent the amount for the Quarter ended March 31 2026 (Audited) is 58.64 Lakhs and amount for the Quarter ended December 31 2025 (Unaudited) is 58.31 Lakhs and amount for the Quarter ended March 31 2025 (Unaudited) is 55.09 Lakhs and amount for the Year ended March 31 2026 (Audited) is 231.76 Lakhs and amount for the Year ended March 31 2025 Audited is 214.20 Lakhs. For Legal and professional fees the amount for the Quarter ended March 31 2026 (Audited) is 95.53 Lakhs and amount for the Quarter ended December 31 2025 (Unaudited) is 43.85 Lakhs and amount for the Quarter ended March 31 2025 (Unaudited) is 49.20 Lakhs and amount for the Year ended March 31 2026 (Audited) is 265.83 Lakhs and amount for the Year ended March 31 2025 (Audited) is 183.79 Lakhs.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Amount of items that will not be reclassified to profit and loss 2.39 10.12
Total Amount of items that will not be reclassified to profit and loss 2.39 10.12
2 Income tax relating to items that will not be reclassified to profit or loss 0.60 2.55
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 1.79 7.57



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2,926.55
Adjustments for reconcile profit (loss)
Adjustments for finance costs 336.19
Adjustments for decrease (increase) in inventories 24.60
Adjustments for decrease (increase) in trade receivables, current (1,924.73)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 54.55
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 1.97
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 112.87
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 62.48
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 243.66
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 40.33
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 7.09
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 47.96
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 10.13
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,078.82)
Net cash flows from (used in) operations 1,847.73
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,120.39
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 727.34
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 1.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 12.22
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 458.51
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 12.27
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (8,106.77)
Net cash flows from (used in) investing activities (8,564.23)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 9,000.08
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,687.37
Repayments of borrowings 1,470.85
Payments of lease liabilities 32.03
Dividends paid 0.00
Interest paid 313.55
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (853.27)
Net cash flows from (used in) financing activities 8,017.75
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 180.86
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 180.86
Cash and cash equivalents cash flow statement at beginning of period 672.83
Cash and cash equivalents cash flow statement at end of period 853.69





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S K G N & Associates LLP Yes 31-12-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 27-02-2026
Amount Raised 9,000.08
Report filed for Quarter ended 31-03-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable Infomerics Valuation and Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review NA
Comments of the auditors, if any NA
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Signatory Details

Name of signatory Rakesh Kumar Sharma
Designation of person Chief Financial Officer
Place New Delhi
Date 28-05-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Gaudium IVF and Women Health Limited Dr. Manika Khanna Chairperson and Managing Director Any other transaction Professional Fees 90.00 Approved by Audit Committee, where required 90.00 13.50 2.62
2 Gaudium IVF and Women Health Limited Dr. Manika Khanna Chairperson and Managing Director Any other transaction Rent 48.00 Approved by Audit Committee, where required 48.00 0.00 0.00
3 Gaudium IVF and Women Health Limited Dr. Peeyush Khanna Whole Time Director Remuneration 12.00 Approved by Audit Committee, where required 12.00 1.62 1.67
4 Gaudium IVF and Women Health Limited Dr. Peeyush Khanna Whole Time Director Any other transaction Professional Fees 18.00 Approved by Audit Committee, where required 18.00 2.70 2.70
5 Gaudium IVF and Women Health Limited Mr. Vishad Khanna Non-Executive Director Any other transaction Purchase of investment in EKK Global Private Limited 0.51 Approved by Audit Committee, where required 0.51 0.00 0.00
6 Gaudium IVF and Women Health Limited Gaudium International Private Limited Subsidiary Purchase of goods or services 185.24 Approved by Audit Committee, where required 185.24 27.71 38.95
7 Gaudium IVF and Women Health Limited Gaudium International Private Limited Subsidiary Any other transaction Rent paid on machinery 4.50 Approved by Audit Committee, where required 4.50 0.00 0.00
8 Gaudium International Private Limited Dr. Manika Khanna Non-Executive Director Any other transaction Rent expense 12.00 Approved by Audit Committee, where required 12.00 0.00 0.00
9 Gaudium International Private Limited Dr. Peeyush Khanna Non-Executive Director Any other transaction Rent expense 6.00 Approved by Audit Committee, where required 6.00 0.00 0.00
10 Gaudium IVF and Women Health Limited Dr. Manika Khanna Chairperson and Managing Director Any other transaction Purchase of investment in EKK Global Private Limited 0.49 Approved by Audit Committee, where required 0.49 0.00 0.00
11 Gaudium International Private Limited EKK Global Private Limited Enterprises where Directors are Interested Any other transaction Purchase 13.78 Approved by Audit Committee, where required 13.78 0.00 104.10
Total value of transaction during the reporting period 390.52